Larvol Delta - CO44657-A-Study-to-Evaluate-Efficacy-and-Safety-of-Giredestrant-Compared-With-Fulvestrant-Plus-a-CDK46-Inhibitor-in-Participants-With-ERPositive-HER2Negative-Advanced-Breast-Cancer-Resistant-to-Adjuvant-Endocrine-Therapy-pionERA-Breast-Cancer

giredestrant (RG6171) - Roche

Kisqali (ribociclib) - Novartis

Ibrance (palbociclib) - Pfizer

Verzenio (abemaciclib) - Eli Lilly

fulvestrant - Generic mfg.

http://clinicaltrials.gov/ct2/show/NCT06065748

Sep 14, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next